LifeSpan Vision Ventures has closed an investment in Remedium Bio. The funding will be used to advance the company’s lead candidate, RMD-1202, towards Phase 1 studies. RMD-1202 delivers a GLP-1 receptor agonist and demonstrates weight loss, glycemic control, and insulin response superior to daily GLP-1 protein injections – with a potentially increased safety and tolerability profile.
Read also – NYC-based Versana Raises $26 Million in Funding
The platform can deliver a broad range of proteins, from peptides to antibodies and Remedium is developing additional therapies across musculoskeletal, immunology, and neurology disorders.
Read also – Pieces Technologies Raises $25 Million in Growth Funding
The biotechnology company is developing a first-in-class adjustable-dose gene therapy platform called Prometheus™, which can replace a broad range of multi-protein injection treatments with a single injection, dose adjustable, gene therapy. The treatment, which is administered by a subcutaneous injection, is highly safe, localized, durable, and costs less than many protein-based therapeutics. Unlike with therapeutic protein injections, Prometheus™ delivers stable, durable, and consistent protein expression, eliminating the concentration spikes that can limit the safety and efficacy of treatments delivered via repeat injection.
Andrew Worden, Founding Partner at LifeSpan Vision Ventures, said “Our mission is to invest in companies that support and accelerate the development of therapies that extend healthspan and address age-related challenges. We believe that Remedium’s technology can be applied across a broad range of age-related diseases and opens the potential of gene therapy to vast markets. We are delighted to be supporting Frank and his team to take the company to the next level.”
Frank Luppino, President and CEO of Remedium Bio, stated “We are extremely excited to welcome Lifespan Vision Ventures as an investor in Remedium Bio. Our Prometheus™ platform is a significant advance in genetic medicine, one that brings the benefits of gene therapy to large unmet needs affecting how we age. Lifespan, with their strong grounding in the science and experience growing innovative companies, is an ideal partner to support Remedium as we enter an exciting new phase in our evolution.”
About Remedium Bio
Remedium Bio is a biotechnology company focused on the development of treatments for large unmet clinical needs. To enable this, we developed a revolutionary gene therapy platform, which enables safe, effective, and durable delivery of therapeutic genes while allowing for simple post-treatment dose adjustment. The Prometheus™ adjustable gene therapy platform enables replacement of a broad range of subcutaneously administered protein treatments with a single injection, adjustable dose gene therapy.
The system has an exceptionally high degree of specificity and remains localized to the site of the subcutaneous injection, offering a safe and durable, single injection alternative, at a fraction of the current protein-based therapeutic treatment cost. Remedium’s pipeline includes several disease modifying treatments with unprecedented efficacy in the fields of endocrinology (weight loss and type 2 diabetes), immunology, neurology, and musculoskeletal diseases
